SOLARA — Solara Active Pharma Sciences Share News
0.000.00%
Last trade - 00:00- IN₹29.41bn
- IN₹34.56bn
- IN₹13.69bn
India's Solara Active Pharma Sciences sees best day in almost a month
Brief: India's Solara Active Pharma Sciences Reports June-Quarter Consol Net Loss
Brief: Solara Active Pharma Sciences March-Qtr Consol Net Profit Falls
Brief: Solara Active Pharma Sciences Named Rajender Juvvadi Rao MD & CEO
Brief: Solara Active Pharma Sciences Posts Dec-Qtr Consol Net Loss
Brief: Solara Active Pharma Says Approved Amalgamation Amongst Co, Hydra Active Pharma, Aurore Life Sciences, Empyrean Lifesciences
Brief: Solara Active Pharma Sciences Sept-Quarter Consol Net Profit Falls
Brief: India's Solara Says Suitability Certificate For Ranitidine Hydrochloride Drug Substance Restored
Brief: Solara Active Pharma Sciences March Qtr Consol Net Profit Rises
Brief: Solara Active Pharma Sciences Says Board Approved Amalgamation Of Aurore, Empyrean And Hydra With Co
Brief: India's Solara Active Pharma Sciences Dec-Qtr Consol Profit Rises
Brief: Solara Active Pharma Sciences Says Declared Interim Dividend Of 4 Rupees Per Share
Brief: India's Solara Active Pharma Sciences Sept-Qtr Consol Net Profit 566.7 Mln Rupees
Brief: Solara Active Pharma Sciences Commences Phase 1 At Vizag Facility
Brief: Solara Active Pharma Sciences June Quarter Consol Profit Rises
Brief: Solara Active Pharma Sciences Says FDA Informed Co About Classifying Manufacturing Site At Cuddalore As "Official Action Indicated"
Brief: India's Solara Active Pharma Reports Lower March-Quarter Profit
Brief: Solara Active Pharma Sciences Updates On Ranitidine Hydrochloride API
Solara Active Pharma hits 13-yr high on U.S. FDA inspection success